Victory Capital Management Inc. Purchases 51,345 Shares of Cencora, Inc. (NYSE:COR)

Victory Capital Management Inc. boosted its position in Cencora, Inc. (NYSE:COR - Free Report) by 25.2% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 255,425 shares of the company's stock after purchasing an additional 51,345 shares during the quarter. Victory Capital Management Inc. owned about 0.13% of Cencora worth $57,389,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the company. Pacer Advisors Inc. increased its stake in Cencora by 6,855.3% during the 3rd quarter. Pacer Advisors Inc. now owns 2,065,374 shares of the company's stock valued at $464,874,000 after buying an additional 2,035,679 shares during the period. Wellington Management Group LLP increased its stake in Cencora by 7.0% during the 3rd quarter. Wellington Management Group LLP now owns 5,193,386 shares of the company's stock valued at $1,168,927,000 after buying an additional 338,452 shares during the period. Nordea Investment Management AB increased its stake in Cencora by 40.2% during the 4th quarter. Nordea Investment Management AB now owns 1,077,272 shares of the company's stock valued at $243,173,000 after buying an additional 308,773 shares during the period. Two Sigma Advisers LP increased its stake in Cencora by 21.7% during the 3rd quarter. Two Sigma Advisers LP now owns 1,638,400 shares of the company's stock valued at $368,771,000 after buying an additional 292,600 shares during the period. Finally, State Street Corp increased its stake in Cencora by 3.8% during the 3rd quarter. State Street Corp now owns 8,045,896 shares of the company's stock valued at $1,810,970,000 after buying an additional 291,867 shares during the period. 97.52% of the stock is currently owned by institutional investors.

Remove Ads

Cencora Trading Up 0.3 %

Shares of COR traded up $0.77 during midday trading on Friday, hitting $254.54. The stock had a trading volume of 2,250,571 shares, compared to its average volume of 1,521,899. Cencora, Inc. has a fifty-two week low of $214.77 and a fifty-two week high of $262.26. The business has a 50-day simple moving average of $244.34 and a two-hundred day simple moving average of $238.40. The firm has a market cap of $49.36 billion, a P/E ratio of 36.21, a price-to-earnings-growth ratio of 1.31 and a beta of 0.51. The company has a current ratio of 0.92, a quick ratio of 0.54 and a debt-to-equity ratio of 16.40.

Cencora (NYSE:COR - Get Free Report) last posted its quarterly earnings results on Wednesday, February 5th. The company reported $3.73 EPS for the quarter, topping the consensus estimate of $3.50 by $0.23. Cencora had a net margin of 0.46% and a return on equity of 328.62%. As a group, equities analysts forecast that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, March 3rd. Investors of record on Friday, February 14th were issued a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a dividend yield of 0.86%. The ex-dividend date was Friday, February 14th. Cencora's dividend payout ratio is currently 31.29%.

Wall Street Analysts Forecast Growth

COR has been the topic of several research analyst reports. Wells Fargo & Company raised their target price on shares of Cencora from $237.00 to $251.00 and gave the company an "equal weight" rating in a research note on Wednesday, January 29th. StockNews.com cut shares of Cencora from a "buy" rating to a "hold" rating in a research note on Tuesday, March 4th. Mizuho initiated coverage on shares of Cencora in a research note on Wednesday, December 4th. They issued an "outperform" rating and a $280.00 price objective on the stock. JPMorgan Chase & Co. lifted their price objective on shares of Cencora from $289.00 to $301.00 and gave the stock an "overweight" rating in a research note on Friday, January 24th. Finally, Evercore ISI lifted their price objective on shares of Cencora from $270.00 to $280.00 and gave the stock an "outperform" rating in a research note on Thursday, February 6th. Three analysts have rated the stock with a hold rating and eight have given a buy rating to the company's stock. Based on data from MarketBeat, Cencora currently has an average rating of "Moderate Buy" and an average price target of $277.90.

Insider Buying and Selling

In other Cencora news, CEO Robert P. Mauch sold 4,970 shares of Cencora stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $255.00, for a total value of $1,267,350.00. Following the completion of the sale, the chief executive officer now directly owns 51,070 shares in the company, valued at $13,022,850. The trade was a 8.87 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Silvana Battaglia sold 5,000 shares of Cencora stock in a transaction that occurred on Friday, February 21st. The shares were sold at an average price of $242.24, for a total transaction of $1,211,200.00. Following the completion of the sale, the executive vice president now owns 15,374 shares of the company's stock, valued at $3,724,197.76. This trade represents a 24.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 11,648 shares of company stock worth $2,862,342. 10.80% of the stock is owned by company insiders.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.